Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD
- PMID: 34033923
- DOI: 10.1016/j.cgh.2021.05.029
Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD
Abstract
Background & aims: Metabolic dysfunction-associated fatty liver disease (MAFLD) establishes new criteria for diagnosing fatty liver disease independent of alcohol intake and concomitant viral hepatitis infection. However, the long-term outcomes of patients with MAFLD are sparse. We aimed to describe the characteristics and long-term survival of persons meeting criteria for nonalcoholic fatty liver disease (NAFLD) only (non-MAFLD NAFLD), for both NAFLD and MAFLD (NAFLD-MAFLD), and for MAFLD only (non-NAFLD MAFLD).
Methods: Using data from the Third National Health and Nutrition Examination Survey (NHANES III) 1988-1994, 2997 participants with fatty liver identified via ultrasound were categorized into 3 distinct groups: non-MAFLD NAFLD, NAFLD-MAFLD, and non-NAFLD MAFLD.
Results: Participants in the NAFLD-MAFLD and non-NAFLD MAFLD groups were older, had more metabolic traits and higher mean liver enzymes. Nearly 8% of participants in the non-NAFLD MAFLD group had advanced fibrosis (Fibrosis-4 index >2.67), while only 1.3% and 1.9% in the NAFLD-MAFLD and non-MAFLD NAFLD groups did, respectively (P < .0001). Non-NAFLD MAFLD participants had the highest cumulative incidence of all-cause mortality (26.2%) followed by those with NAFLD-MAFLD then non-MAFLD NAFLD participants (21.1% and 10.6%, respectively; P < .0001). Similar findings were observed for cardiovascular disease-related and other-cause (noncardiovascular disease, noncancer) mortality. Non-NAFLD MAFLD was independently associated with all-cause mortality compared with non-MAFLD NAFLD (adjusted hazard ratio, 2.4; 95% confidence interval, 1.2-4.6; P = .01).
Conclusions: MAFLD criteria identified a significant group of people with more comorbidities and worse prognosis compared with those with NAFLD only. These criteria should be considered in the general population to identify high-risk groups for early interventions.
Keywords: Fatty Liver; MAFLD; Mortality Outcomes; NAFLD.
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Comparison of MAFLD and NAFLD diagnostic criteria in real world.Liver Int. 2020 Sep;40(9):2082-2089. doi: 10.1111/liv.14548. Epub 2020 Jul 26. Liver Int. 2020. PMID: 32478487
-
A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.Hepatol Int. 2022 Aug;16(4):835-845. doi: 10.1007/s12072-022-10362-3. Epub 2022 Jun 14. Hepatol Int. 2022. PMID: 35701716
-
MAFLD and risk of CKD.Metabolism. 2021 Feb;115:154433. doi: 10.1016/j.metabol.2020.154433. Epub 2020 Nov 16. Metabolism. 2021. PMID: 33212070
-
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name.Clin Mol Hepatol. 2022 Oct;28(4):790-801. doi: 10.3350/cmh.2022.0070. Epub 2022 May 11. Clin Mol Hepatol. 2022. PMID: 35545437 Free PMC article. Review.
-
Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.Eur J Clin Invest. 2021 Jul;51(7):e13519. doi: 10.1111/eci.13519. Epub 2021 Mar 2. Eur J Clin Invest. 2021. PMID: 33583033 Review.
Cited by
-
MAFLD: How is it different from NAFLD?Clin Mol Hepatol. 2023 Feb;29(Suppl):S17-S31. doi: 10.3350/cmh.2022.0367. Epub 2022 Nov 29. Clin Mol Hepatol. 2023. PMID: 36443926 Free PMC article. Review.
-
Association between low-normal thyroid function and advanced liver fibrosis in metabolic dysfunction-associated fatty liver disease patients: a retrospective cohort study.Gastroenterol Rep (Oxf). 2024 Jan 22;12:goad076. doi: 10.1093/gastro/goad076. eCollection 2024. Gastroenterol Rep (Oxf). 2024. PMID: 38264763 Free PMC article.
-
Usefulness of a questionnaire for assessing the relationship between eating behavior and steatotic liver disease among Japanese male young adults.Sci Rep. 2024 Jan 25;14(1):2194. doi: 10.1038/s41598-024-52797-8. Sci Rep. 2024. PMID: 38273030 Free PMC article.
-
Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD.Sci Rep. 2024 Jun 11;14(1):13411. doi: 10.1038/s41598-024-64301-3. Sci Rep. 2024. PMID: 38862756 Free PMC article.
-
Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective.Hepatol Int. 2024 Oct;18(Suppl 2):959-976. doi: 10.1007/s12072-024-10663-9. Epub 2024 May 8. Hepatol Int. 2024. PMID: 38717691 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical